Multiple therapies relieve long-term tardive dyskinesia in a patient with chronic schizophrenia: A case report.

World journal of clinical cases 2023 Vol.11(32) p. 7895-7899

Lv L, Guo P, Feng M, Fang Y, Wang SK, Chen HX

관련 도메인

Abstract

[BACKGROUND] Tardive dyskinesia (TD) is a serious and disabling movement disorder; it impairs social function and quality of life and increases the mortality rate. TD is usually induced by the use of antipsychotic drugs; however, the underlying mechanism remains unclear. Pharmacotherapy of TD includes cholinergic drugs, benzodiazepines, ginkgo biloba extract (GBE), antioxidants, amantadine, propanolol, botulinum toxin, valbenazine, and deutetrabenazine, whereas the non-pharmacotherapy approach includes modified electroconvulsive therapy (MECT) and deep brain stimulation. We successfully treated a chronic schizophrenia patient with comorbid long-term severe TD using deutetrabenazine, clozapine, and MECT.

[CASE SUMMARY] A 69-year-old woman who was diagnosed as having schizophrenia 16 years ago developed severe TD after 6-mo prescription of risperidone oral solution. Her TD symptoms did not resolve despite various treatments, such as GBE, vitamin E, trihexyphenidyl, promethazine, benzodiazepines, and switching to quetiapine and olanzapine. After admission, she was given deutetrabenazine 6 mg bid. Her buccal tremor was slightly resolved 3 d later; however, her tongue remained protruded and could not be retracted. Quetiapine was switched to clozapine on day 4, and the buccal tremor remarkably resolved, and the tongue could be retracted into the mouth from day 6 onward. After three sessions of MECT, the buccal tremor resolved further. Since then, she has been able to take a semifluid diet, and her quality of life improved remarkably during 6 mo of follow-up.

[CONCLUSION] TD is a serious condition which could be caused by antipsychotic medications; however, the best strategy against TD is prevention and monitoring during using antipsychotics. For patients with TD caused by antipsychotic medication use, multiple measures should be considered like switching to clozapine, adjunction with deutetrabenazine, or even MECT.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1
해부 brain scispacy 1
해부 oral scispacy 1
해부 tongue scispacy 1
합병증 buccal tremor scispacy 1
합병증 buccal scispacy 1
합병증 mouth scispacy 1
약물 benzodiazepines C0005064
Benzodiazepines
scispacy 1
약물 ginkgo biloba extract C0772125
Ginkgo biloba extract
scispacy 1
약물 GBE → ginkgo biloba extract C0772125
Ginkgo biloba extract
scispacy 1
약물 amantadine C0002403
amantadine
scispacy 1
약물 propanolol C0033497
propranolol
scispacy 1
약물 valbenazine C4078701
valbenazine
scispacy 1
약물 clozapine C0009079
clozapine
scispacy 1
약물 risperidone C0073393
risperidone
scispacy 1
약물 vitamin E C0042874
vitamin E
scispacy 1
약물 trihexyphenidyl C0041009
trihexyphenidyl
scispacy 1
약물 promethazine C0033405
promethazine
scispacy 1
약물 quetiapine C0123091
quetiapine
scispacy 1
약물 olanzapine C0171023
olanzapine
scispacy 1
약물 [BACKGROUND] scispacy 1
약물 botulinum scispacy 1
약물 deutetrabenazine scispacy 1
약물 [CONCLUSION] TD scispacy 1
질환 tardive dyskinesia C0686347
Tardive Dyskinesia
scispacy 1
질환 schizophrenia C0036341
Schizophrenia
scispacy 1
질환 movement disorder C0026650
Movement Disorders
scispacy 1
질환 comorbid long-term severe TD scispacy 1
질환 tremor C0040822
Tremor
scispacy 1
기타 patient scispacy 1
기타 patients scispacy 1

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문